

Kapsch TrafficCom Holding Corp.,
8201 Greensboro Drive, Suite 1002,
McLean, VA 22102.

Kapsch TrafficCom Canada, Inc., 6020
Ambler Drive, Mississauga, ON L4W
2P1, Canada.

Star Systems International, Ltd., Unit
A01, 24/F Gold King Industrial
Building, 35–41 Tai Lin Pai Road, Kwai
Chung, Hong Kong.

STAR RFID Co., Ltd., 1 Charoenrat
Road, Thung Wat Don, Sathon, Bangkok
10120 Thailand.

(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW., Suite
401, Washington, DC 20436;

(3) Pursuant to Commission Rule
210.50(b)(1), 19 CFR 210.50(b)(1), the
presiding administrative law judge shall
take evidence or other information and
hear arguments from the parties and
other interested persons with respect to
the public interest in this investigation,
as appropriate, and provide the
Commission with findings of fact and a
recommended determination on this
issue, which shall be limited to the
statutory public interest factors set forth
in 19 U.S.C. 1337(d)(1), (f)(1), (g)(1);

(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.

Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission's Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.

Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.

By order of the Commission.

Issued: January 6, 2016.

Lisa R. Barton,

Secretary to the Commission.

[FR Doc. 2016–00289 Filed 1–8–16; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—R Consortium, Inc.

Notice is hereby given that, on
December 3, 2015, pursuant to section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 *et seq.* (“the Act”), R
Consortium, Inc. (“R Consortium”) has
filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act's provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, 0965688 BC LTD., Surrey,
British Columbia, CANADA, has been
added as a party to this venture.

No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and R Consortium
intends to file additional written
notifications disclosing all changes in
membership.

On September 15, 2015, R Consortium
filed its original notification pursuant to
section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to section
6(b) of the Act on October 2, 2015 (80
FR 59815).

Patricia A. Brink,

*Director of Civil Enforcement, Antitrust
Division.*

[FR Doc. 2016–00323 Filed 1–8–16; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—The Open Group, L.L.C.

Notice is hereby given that, on
December 8, 2015, pursuant to section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 *et seq.* (“the Act”), The
Open Group, L.L.C. (“TOG”) has filed

written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act's provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances.

Specifically, AEGIS.net, Inc.,
Rockville, MD; Air Force Research
Laboratory, Kirtland AFB, NM; Aoyama
Gakuin University, Tokyo, JAPAN; Bank
of Zambia, Lusaka, ZAMBIA; Dunstan
Thomas Consulting, Ltd., Portsmouth,
UNITED KINGDOM; Front Metrics
Technologies Pvt. Ltd., Pune, INDIA;
Geco, Inc., Mesa, AZ; Inspur Co., Ltd.,
Beijing, PEOPLE'S REPUBLIC OF
CHINA; IAB BVBA, Boutersem,
BELGIUM; Intelligent Training de
Columbia, Bogota, COLOMBIA; Joint
Tactical Network Center, San Diego, CA;
M J Anniss, Ltd., Nairn, UNITED
KINGDOM; PLANAD Consultoria em
Gestão Empresarial Ltda., São Paulo,
BRAZIL; SIGMAXYZ Inc., Tokyo,
JAPAN; S.P. Jain Institute of
Management Research, Mumbai, INDIA;
Universidad Continental, Huancayo,
PERU; University of Dayton Research
Institute, Dayton, OH; Vencore, Inc.,
Lexington Park, MD; Vigilance, Inc.,
McLean, VA; and White Cloud Software
Ltd., Bowen Island, CANADA, have
been added as parties to this venture.

Also, Architecture Capability
Assurance Strategic Group, Palo Alto,
CA; ATSI S.A., Zabierzow, POLAND;
AXE, Inc., Nakagyo-ku, JAPAN; Bell
Helicopter Textron Inc., Fort Worth, TX;
CS Interactive Training, Pretoria,
SOUTH AFRICA; EXELIS, Inc., Clifton,
NJ; Fairchild Controls Corporation,
Frederick, MD; Hoople Limited,
Hereford, UNITED KINGDOM; Howell
Instruments, Inc., Fort Worth, TX; Indra
Colombia, Bogota, COLOMBIA;
Kamehameha Schools-Trustees of the
Estate of Bernice Pauahi Bishop,
Honolulu, HI; Korea Software
Technology Association, Gyeonggi-Do,
REPUBLIC OF KOREA; Mobile
Reasoning, Inc., Lenaxa, KS; Nippon
Telegraph & Telephone Corporation,
Tokyo, JAPAN; Online Business
Systems, Winnepeg, CANADA;
PreterLex Limited, Cambridge, UNITED
KINGDOM; University of Nordland,
Oslo, NORWAY; VIP Apps Consulting
Limited, Hertfordshire, UNITED
KINGDOM; and World Vision
International, Monrovia, CA, have
withdrawn as parties to this venture.

In addition, Hewlett Packard
Company has changed its name to
Hewlett Packard Enterprises, Cupertino,
CA.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and TOG intends to file additional written notifications disclosing all changes in membership.

On April 21, 1997, TOG filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on June 13, 1997 (62 FR 32371).

The last notification was filed with the Department on September 9, 2015. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on October 2, 2015 (80 FR 59816).

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2016-00325 Filed 1-8-16; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Importer of Controlled Substances Application: Sharp Clinical Services, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic class, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before February 10, 2016. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before February 10, 2016.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled

substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on July 29, 2015, Sharp Clinical Services, Inc., 300 Kimberton Road, Phoenixville, Pennsylvania 19460 applied to be registered as an importer of marihuana (7360), a basic class of controlled substance listed in schedule I.

The company plans to import finished pharmaceutical products containing cannabis extracts in dosage form for clinical trial studies.

This compound is listed under drug code 7360. No other activity for this drug code is authorized for this registration. Approval of permits applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: January 4, 2016.

Louis J. Milione,

Deputy Assistant Administrator.

[FR Doc. 2016-00214 Filed 1-8-16; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Importer of Controlled Substances Application: Myoderm

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before February 10, 2016. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before February 10, 2016.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing

Clerk/LJ, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on October 9, 2015, Myoderm, 48 East Main Street, Norristown, Pennsylvania 19401 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Schedule
Amphetamine (1100)	II
Lisdexamfetamine (1205)	II
Methylphenidate (1724)	II
Pentobarbital (2270)	II
Nabilone (7379)	II
Codeine (9050)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Hydrocodone (9193)	II
Levomethorphan (9210)	II
Meperidine (9230)	II
Methadone (9250)	II
Methadone intermediate (9254) ...	II
Morphine (9300)	II
Oxymorphone (9652)	II
Fentanyl (9801)	II

The company plans to import the listed controlled substances in finished dosage form for clinical trials, research, and analytical purposes.

The import of the above listed basic classes of controlled substances will be granted only for analytical testing, research, and clinical trials. This authorization does not extend to the import of a finished FDA approved or non-approved dosage form for commercial sale.

Dated: January 4, 2016.

Louis J. Milione,

Deputy Assistant Administrator.

[FR Doc. 2016-00213 Filed 1-8-16; 8:45 am]

BILLING CODE 4410-09-P